New Posts New Posts RSS Feed - IMPORTANT info on ER expression in TNBC
  FAQ FAQ  Forum Search   Events   Register Register  Login Login

IMPORTANT info on ER expression in TNBC

 Post Reply Post Reply Page  12>
Author
Lee21 View Drop Down
Senior Member
Senior Member
Avatar

Joined: Dec 22 2011
Location: Michigan
Status: Offline
Points: 752
Post Options Post Options   Thanks (0) Thanks(0)   Quote Lee21 Quote  Post ReplyReply Direct Link To This Post Topic: IMPORTANT info on ER expression in TNBC
    Posted: Mar 26 2012 at 4:51pm
Definition of ER negativity:
pre 2010 -- <10%
2010 -- < 1%

The change in recommendations from ASCO is based on the belief to not deny any woman treatment if there is a possibility that she can potentially benefit from anti-hormonal therapy.

As far as I can tell, all papers and trials that have been published on TNBC have been using the <10% definition for inclusion.  Perhaps that also contributes to the overall heterogeneity of this group of breast cancers. Answers to some really basic questions are not apparent.  For example, is it the majority or minority of TNBC patients that express <1% ER ?

The topic of low estrogen receptor expression has surfaced previously on this forum but perhaps we haven't looked at it in a systematic fashion as a group.  So I am hoping that we can start a discussion on this. 

I am bringing this up now because both my oncologist as well as My 2nd opinion who I saw in consultation believe that after my current treatment is completed and my tumor at surgery continues to show a tiny amount of ER expression, that I should go on some form of anti-estrogen treatment.


Edited by Lee21 - Apr 03 2012 at 7:53am
12/9/11 @59,IDC,grade3, TNBC,3cm(MRI),SLNB0,stage IIA, BRCA1 variant
1/30/12 DD AC-T, 6/7/12 Lumpectomy, ypT1b(0.8 cm), 7/9/12 Rads x 30
11/9/12, clinical trial cisplatin/rucaparib, cisplatin-only arm
Back to Top
Autumn10182001 View Drop Down
Senior Member
Senior Member
Avatar

Joined: Aug 18 2009
Location: Highland, NY
Status: Offline
Points: 557
Post Options Post Options   Thanks (0) Thanks(0)   Quote Autumn10182001 Quote  Post ReplyReply Direct Link To This Post Posted: Mar 26 2012 at 5:53pm
i was 5% ER+ last time... and my onc has me on femara.... says it might help a little bit.....
DX2/99 Stg I,ER+PR+ Chemo lumpectomy - Neg nodes,rads, tamox,femara. DX4/09, Stg IIB /III, TNBC IDC, Grade III, 2.5CM, mastectomy. 4AC DD,12 wkly taxol,BRAC1&2Neg, Right Mast 11/25/09
Back to Top
Lee21 View Drop Down
Senior Member
Senior Member
Avatar

Joined: Dec 22 2011
Location: Michigan
Status: Offline
Points: 752
Post Options Post Options   Thanks (0) Thanks(0)   Quote Lee21 Quote  Post ReplyReply Direct Link To This Post Posted: Mar 26 2012 at 7:39pm
Autumn,
Just to clarify, you mean when you were diagnosed in 1999, you were 5% ER+ and when you had your recurrence in 2009 the tumor was <1% ER+?
Lee
12/9/11 @59,IDC,grade3, TNBC,3cm(MRI),SLNB0,stage IIA, BRCA1 variant
1/30/12 DD AC-T, 6/7/12 Lumpectomy, ypT1b(0.8 cm), 7/9/12 Rads x 30
11/9/12, clinical trial cisplatin/rucaparib, cisplatin-only arm
Back to Top
Autumn10182001 View Drop Down
Senior Member
Senior Member
Avatar

Joined: Aug 18 2009
Location: Highland, NY
Status: Offline
Points: 557
Post Options Post Options   Thanks (0) Thanks(0)   Quote Autumn10182001 Quote  Post ReplyReply Direct Link To This Post Posted: Mar 26 2012 at 8:12pm
in 1999 i was 90% ER+ and PR+ al;so,   in 2009 my BC was 5% ER+.  but that was considered TNBC at that time
DX2/99 Stg I,ER+PR+ Chemo lumpectomy - Neg nodes,rads, tamox,femara. DX4/09, Stg IIB /III, TNBC IDC, Grade III, 2.5CM, mastectomy. 4AC DD,12 wkly taxol,BRAC1&2Neg, Right Mast 11/25/09
Back to Top
Charlene View Drop Down
Senior Member
Senior Member
Avatar

Joined: Aug 14 2010
Location: Atlanta, GA
Status: Offline
Points: 613
Post Options Post Options   Thanks (0) Thanks(0)   Quote Charlene Quote  Post ReplyReply Direct Link To This Post Posted: Mar 26 2012 at 8:44pm

At my diagnosis in March 2010, my pathology report stated:  ESTROGEN RECEPTOR: 5% (faint).  My oncologist showed me information from Adjuvant Online which stated that less than 1 out of 100 women (with an identical diagnosis) would be helped by hormone therapy.  Prior to my diagnosis, I was on hormone replacement therapy, which I never took again.  I'm just sharing this to be part of the discussion, not to try to influence anyone one way or another.

Charlene
DX 3/10 @59 ILC/TNBC
Stage 1, Grade 2, Multifocal; Lumpectomy/re-excision
SNB 0/4 nodes, BRCA-; Taxotere/Cytoxan X4, 30 rads
3/14:NED
Back to Top
Lee21 View Drop Down
Senior Member
Senior Member
Avatar

Joined: Dec 22 2011
Location: Michigan
Status: Offline
Points: 752
Post Options Post Options   Thanks (0) Thanks(0)   Quote Lee21 Quote  Post ReplyReply Direct Link To This Post Posted: Mar 26 2012 at 8:58pm
Charlene -- thank you for sharing.  I think that if you ask 100 oncologists the question whether to treat or not with <10% ER+, you will likely get a divided response and it may ultimately boils down to whether side effects outweigh potential benefits.
As mentioned, the heterogeneity of ER expression is also a contributory factor to the heterogeneity seen at the molecular level with TNBC.
If TNBC trials start restricting enrollment to those with ER <1 %, as some have advocated, it will leave those of us with ER 1-9% in never-never land.


Edited by Lee21 - Mar 26 2012 at 9:00pm
12/9/11 @59,IDC,grade3, TNBC,3cm(MRI),SLNB0,stage IIA, BRCA1 variant
1/30/12 DD AC-T, 6/7/12 Lumpectomy, ypT1b(0.8 cm), 7/9/12 Rads x 30
11/9/12, clinical trial cisplatin/rucaparib, cisplatin-only arm
Back to Top
Lee21 View Drop Down
Senior Member
Senior Member
Avatar

Joined: Dec 22 2011
Location: Michigan
Status: Offline
Points: 752
Post Options Post Options   Thanks (0) Thanks(0)   Quote Lee21 Quote  Post ReplyReply Direct Link To This Post Posted: Mar 27 2012 at 12:54pm
I should mention that Adjuvant Online's current version is from 2006 and does not separate out Her2+ from TNBC (i.e. all ER-).  ER status is restricted to + or - (I assume based on the 10% cutoff).
There is supposed to be a new version (v9) soon.

The 1% cutoff for ER positivity is a new guideline based on a clinical trial that showed efficacy of anti-estrogen treatment using this cutoff (My 2nd opinion mentioned the trial but I have not found the paper yet). 

I hope that more will share their ER status so that we can have an in depth discussion on this very important topic. It is the closest we have to validated targeted therapy other than PARP inhibitors which theoretically should benefit those with BRCAness. Unfortunately, most of us don't know if our tumors fall into that category. BTW, platinum drugs haven't been proven as of this date to be of use to TNBC patients in general other than preliminary subset analysis of very small numbers of patients with BRCA1/2 mutations.


Edited by Lee21 - Apr 03 2012 at 7:54am
12/9/11 @59,IDC,grade3, TNBC,3cm(MRI),SLNB0,stage IIA, BRCA1 variant
1/30/12 DD AC-T, 6/7/12 Lumpectomy, ypT1b(0.8 cm), 7/9/12 Rads x 30
11/9/12, clinical trial cisplatin/rucaparib, cisplatin-only arm
Back to Top
Grateful for today View Drop Down
Senior Member
Senior Member
Avatar

Joined: Sep 21 2011
Location: U.S.A.
Status: Offline
Points: 1835
Post Options Post Options   Thanks (0) Thanks(0)   Quote Grateful for today Quote  Post ReplyReply Direct Link To This Post Posted: Mar 31 2012 at 7:07pm
Hi,

Lee, thanks for pointing out:   Definition of ER negativity:
                                                           pre 2010 -- <10%
                                                           2010 -- < 1%

Per my path report:
        estrogen receptor:          negative   (0%)
                         criteria for hormone receptor analysis:
                                   positive                      >10% of nuclei immunoreactive
                                   positive - low           >   0%      ---       <10% of nuclei immunoreactive
                                   negative                     0% of nuclei immunoreactive

In view of 2010 ER negativity definition being <1% ......wondering if current or any recently
completed clinical trials will report their findings both ways.......for TNBC with ER <1% and
for TNBC with ER<10%.....now, wouldn't that be great!

Thank you for sharing that your consult MD would consider some form of anti-estrogen treatment
if tumor at surgery continues to show a tiny amount of ER expression.   This would be something
one could discuss with one's physician if one was in that situation.


With caring and positive thoughts,

Grateful for today..........Judy
Back to Top
Lee21 View Drop Down
Senior Member
Senior Member
Avatar

Joined: Dec 22 2011
Location: Michigan
Status: Offline
Points: 752
Post Options Post Options   Thanks (0) Thanks(0)   Quote Lee21 Quote  Post ReplyReply Direct Link To This Post Posted: Apr 01 2012 at 5:13pm
Judy,

Thank you for sharing.

I just updated the post in OPEN ACCESS under Low hormone receptor expression:
http://forum.tnbcfoundation.org/topic9440_post97583.html#97583
- to include the position paper from ASCO and College of American Pathologists on the recommendations for ER, PR positivity to be >1% and for anti-estrogen therapy to be given to these patients.

This is an open access article.

A few other things I found out that I would like to share:

Ongoing and recent trials with "triple negative breast cancer" in their titles (in clinicaltrials.gov):
I went through about 60 trials or so (not all yet) and found:
  • some trials just say ER-, PR-
  • most trials define ER-, PR- as being <10% staining
  • a couple of trials define ER-, PR- as <1%
  • one trial defined negativity as <5%
Proportion of BC patients with different levels of ER staining:

1) from JCO 30:729, 2012
total patients = 465
ER < 1% = 39.4 %
ER 1-9% = 5.4 %
ER 10% = 1.2 %
ER > 10% = 54 %

2) from Cancer 118:1498, 2012
total 1257 patients (only ER <=10%)
ER < 1% = 71.4%
ER 1-5% = 19.2%
ER 6-10% = 9.4%

It would seem that there are more patients at the extreme ends of the ER spectrum: either >10% or <1%.

As the position paper discussed, there is variability in receptor IHC measurments from lab to lab.

Lee

12/9/11 @59,IDC,grade3, TNBC,3cm(MRI),SLNB0,stage IIA, BRCA1 variant
1/30/12 DD AC-T, 6/7/12 Lumpectomy, ypT1b(0.8 cm), 7/9/12 Rads x 30
11/9/12, clinical trial cisplatin/rucaparib, cisplatin-only arm
Back to Top
mainsailset View Drop Down
Senior Member
Senior Member
Avatar

Joined: Jul 27 2008
Location: Washington State
Status: Offline
Points: 5004
Post Options Post Options   Thanks (0) Thanks(0)   Quote mainsailset Quote  Post ReplyReply Direct Link To This Post Posted: Apr 01 2012 at 6:07pm
Well mine, done in 2008, was not even that informative. The path states ER: Negative (score of 0/3)
  PR: Negative (score 0/3)  HER-2 Negative for overexpression (1/3) I always assumed I was in the zero category, but a pretty sketchy guesstimate.
 
dx 7/08 TN 14x6.5x5.5 cm tumor

3 Lymph nodes involved, Taxol/Sunitab+AC, 5/09 dbl masectomy, path 2mm tumor removed, lymphs all clear, RAD 32 finished 9/11/09. 9/28 CT clear 10/18/10 CT clear
Back to Top
krisa View Drop Down
Senior Member
Senior Member
Avatar

Joined: May 21 2008
Location: Portland, OR
Status: Offline
Points: 1090
Post Options Post Options   Thanks (0) Thanks(0)   Quote krisa Quote  Post ReplyReply Direct Link To This Post Posted: Apr 01 2012 at 6:29pm
I had a progesterone % listed on my path report, but no estrogen %.
Back to Top
Lee21 View Drop Down
Senior Member
Senior Member
Avatar

Joined: Dec 22 2011
Location: Michigan
Status: Offline
Points: 752
Post Options Post Options   Thanks (0) Thanks(0)   Quote Lee21 Quote  Post ReplyReply Direct Link To This Post Posted: Apr 01 2012 at 6:32pm
Mainy

On the breast cancer.org website, I found a description of 3 methods to assess hormone receptor expression:
http://www.breastcancer.org/symptoms/testing/types/ihc.jsp
Yours was one of the 3 listed, unfortunately as you stated, not very informative.

Apparently there was a lot of lab-to-lab variation in the staining protocol used as well as subjectivity of the pathologist who did the scoring, necessitating the position paper from ASCO and the College of Pathologists. I wonder if it would be worthwhile on your next visit to the doctor to re-address the issue with them.  Perhaps their thinking has changed since it has been several years (so GLAD you are NED).

Lee
12/9/11 @59,IDC,grade3, TNBC,3cm(MRI),SLNB0,stage IIA, BRCA1 variant
1/30/12 DD AC-T, 6/7/12 Lumpectomy, ypT1b(0.8 cm), 7/9/12 Rads x 30
11/9/12, clinical trial cisplatin/rucaparib, cisplatin-only arm
Back to Top
Lee21 View Drop Down
Senior Member
Senior Member
Avatar

Joined: Dec 22 2011
Location: Michigan
Status: Offline
Points: 752
Post Options Post Options   Thanks (0) Thanks(0)   Quote Lee21 Quote  Post ReplyReply Direct Link To This Post Posted: Apr 01 2012 at 6:35pm
Krisa,
Your ER result is probably buried there somewhere.  Worth thinking about revisiting the issue with your doctor at your next visit. Some think that PR status is an independent prognosticator.
Lee
12/9/11 @59,IDC,grade3, TNBC,3cm(MRI),SLNB0,stage IIA, BRCA1 variant
1/30/12 DD AC-T, 6/7/12 Lumpectomy, ypT1b(0.8 cm), 7/9/12 Rads x 30
11/9/12, clinical trial cisplatin/rucaparib, cisplatin-only arm
Back to Top
mainsailset View Drop Down
Senior Member
Senior Member
Avatar

Joined: Jul 27 2008
Location: Washington State
Status: Offline
Points: 5004
Post Options Post Options   Thanks (0) Thanks(0)   Quote mainsailset Quote  Post ReplyReply Direct Link To This Post Posted: Apr 01 2012 at 6:50pm
WIth all the bussle around getting 2nd and 3rd opinions, I cotinually grind my teeth when I think that so many of the 2nd opinions still base their opinions on the same set of scans and path reports. I thought at the time that it was strange to start out at my local clinic for a biopsy, have them do the report and then take that set of results to a large institute (Fred Hutch) where they did not perform a 2nd biopsy, just for their own benefit (and mine!).
 
We see the opportunity for oversight and sometimes just old fashioned human error often and it would seem prudent to double check the foundation basis of our whole treatment...just sayin
dx 7/08 TN 14x6.5x5.5 cm tumor

3 Lymph nodes involved, Taxol/Sunitab+AC, 5/09 dbl masectomy, path 2mm tumor removed, lymphs all clear, RAD 32 finished 9/11/09. 9/28 CT clear 10/18/10 CT clear
Back to Top
Lee21 View Drop Down
Senior Member
Senior Member
Avatar

Joined: Dec 22 2011
Location: Michigan
Status: Offline
Points: 752
Post Options Post Options   Thanks (0) Thanks(0)   Quote Lee21 Quote  Post ReplyReply Direct Link To This Post Posted: Apr 01 2012 at 6:58pm
They should have plenty left over from the original biopsy (4 core biopsy yields quite a bit of material) which is preserved as a formalin fixed paraffin embedded block.  Additional sections can be made from this block and stained using more standardized methodology.

Having said this, I know what you mean -- I've had two 2nd opinions so far, in one case they wanted the stained sections so I hand carried them but they never looked at them and in the other case, they didn't want the sections to begin with.
12/9/11 @59,IDC,grade3, TNBC,3cm(MRI),SLNB0,stage IIA, BRCA1 variant
1/30/12 DD AC-T, 6/7/12 Lumpectomy, ypT1b(0.8 cm), 7/9/12 Rads x 30
11/9/12, clinical trial cisplatin/rucaparib, cisplatin-only arm
Back to Top
Grateful for today View Drop Down
Senior Member
Senior Member
Avatar

Joined: Sep 21 2011
Location: U.S.A.
Status: Offline
Points: 1835
Post Options Post Options   Thanks (0) Thanks(0)   Quote Grateful for today Quote  Post ReplyReply Direct Link To This Post Posted: Apr 01 2012 at 7:06pm
Mainy and all,

Sharing a thought.

At my 2nd opinion, the 2nd facility pathologist reviewed my slides from where I had my biopsy done.
At least, the 2nd facility had their pathologist's and the 1st facility's pathologist opinion for the consult.
So, when one has a 2nd opinion, one might want to confirm that one would bring one's slides   ( some
places want them sent ahead of time.......be proactive and keep track how the slides are handled, mailed
etc.) for a 2nd pathology opinion as part of the consult.   This is probably being done at some places....
not sure if done at all......and may not be offered at some centers.   In my situation, both pathology
reports were in agreement.

Mainy, your post raises a possible general question to consider ( especially when plan is
neoadjuvant chemo) that I had not thought of before:
     Did one's 1st facility obtain the best biopsy specimen to base treatment on?
    To all who posted above, not questioning anyone's pathology results just thinking of a possible
             consideration after reading Mainy's post.

Grateful for today...............Judy

Edited by Grateful for today - Apr 01 2012 at 11:00pm
Back to Top
Lee21 View Drop Down
Senior Member
Senior Member
Avatar

Joined: Dec 22 2011
Location: Michigan
Status: Offline
Points: 752
Post Options Post Options   Thanks (0) Thanks(0)   Quote Lee21 Quote  Post ReplyReply Direct Link To This Post Posted: Apr 03 2012 at 1:08pm
More on the accuracy of ER, PR testing.
Information obtained from
Practical implications of gene-expression-based assays for breast oncologists
http://www.nature.com/nrclinonc/journal/v9/n1/full/nrclinonc.2011.178.html

Kappa, k, statistic - is commonly used to assess reproducibiliy (-1 to +1)
-1 total discordance
+1 total concordance
0.4-0.6 moderate concordance (level 3 agreement)
0.61-0.8 substantial concordance (level 2)
>= 0.81 almost perfect concordance (level 1)

  • level 1 concordance can only be achieved when the same protocol is used with the same antibodies for IHC assays
  • current results in the clinical setting where different antibodies for ER and PR are allowed, the concordance is between level 2 and level 3
  • 80% of laboratories tested are able to show moderate to high ER expression levels but only 37% scored adequately for low-expressing tumors
  • Her2 IHC testing (see OPEN ACCESS Her2 testing posting) also falls within level 2-3
  • histological grade as assessed by 2 or more pathologists also fall between level 2-3
Apparently, even when path reports sound so definitive, the fact of the matter is that they are not.
12/9/11 @59,IDC,grade3, TNBC,3cm(MRI),SLNB0,stage IIA, BRCA1 variant
1/30/12 DD AC-T, 6/7/12 Lumpectomy, ypT1b(0.8 cm), 7/9/12 Rads x 30
11/9/12, clinical trial cisplatin/rucaparib, cisplatin-only arm
Back to Top
mainsailset View Drop Down
Senior Member
Senior Member
Avatar

Joined: Jul 27 2008
Location: Washington State
Status: Offline
Points: 5004
Post Options Post Options   Thanks (0) Thanks(0)   Quote mainsailset Quote  Post ReplyReply Direct Link To This Post Posted: Apr 03 2012 at 2:09pm
Judy, yes that is a good question to ponder. In my case Fred Hutch did not ask for any samples, only the written reports. Now that I can look back and have had the experience where techs have completely missed out on accuracy, despite the best human efforts possible, I have to wonder if any number of things could occur...actual mix up of slides and files...that again since these are the foundation of your whole treatment wouldn't it be wise to double check with a 2nd biopsy and review and not even just a 2nd set of eyes on the sample? I'm sure in the balance of all things considered, the cost of a 2nd biopsy is pretty darn small.
 
In my sis's case, the biopsy actually ate up her tumor and then of course they lost the samples. Stuff happens.
 
dx 7/08 TN 14x6.5x5.5 cm tumor

3 Lymph nodes involved, Taxol/Sunitab+AC, 5/09 dbl masectomy, path 2mm tumor removed, lymphs all clear, RAD 32 finished 9/11/09. 9/28 CT clear 10/18/10 CT clear
Back to Top
debB View Drop Down
Senior Member
Senior Member
Avatar

Joined: Sep 14 2011
Location: Central Illinoi
Status: Offline
Points: 692
Post Options Post Options   Thanks (0) Thanks(0)   Quote debB Quote  Post ReplyReply Direct Link To This Post Posted: Apr 03 2012 at 2:51pm
Now you all make me wonder!! When I went for a second opinion for surgery, they wanted my slides, which I provided. BUT, I never saw a new pathology report generated from it, so I don't know if they even looked at them. AND, I have no clue where those slides now reside! If they were kept at the second facility or returned to the first! or how I go about finding out, should I decide it is important!

Deb
Dx 4/29/11, 46 yrs old, 3.9 cm tumor, Stg 2 Grade 3 chemo 4 rounds DD AC, 12 weekly taxol, finish. Lumpectomy, 2mm residual tumor. 37 rounds rads completed. Cisplatin/PARP trial
Back to Top
Lee21 View Drop Down
Senior Member
Senior Member
Avatar

Joined: Dec 22 2011
Location: Michigan
Status: Offline
Points: 752
Post Options Post Options   Thanks (0) Thanks(0)   Quote Lee21 Quote  Post ReplyReply Direct Link To This Post Posted: Apr 03 2012 at 3:55pm
Deb
You can ask the second facility to send it back to the first if they haven't done so already.  If they did get lost, the first facility should still have the paraffin block and additional sections can be cut and stained. When I took mine for my 2nd opinion, I asked for them back the next day and hand carried them to my cancer center here. On a related matter, every time I have an imaging test done, I asked for the images to be copied onto a DVD and I hold onto them. 
Lee
12/9/11 @59,IDC,grade3, TNBC,3cm(MRI),SLNB0,stage IIA, BRCA1 variant
1/30/12 DD AC-T, 6/7/12 Lumpectomy, ypT1b(0.8 cm), 7/9/12 Rads x 30
11/9/12, clinical trial cisplatin/rucaparib, cisplatin-only arm
Back to Top
 Post Reply Post Reply Page  12>
  Share Topic   

Forum Jump Forum Permissions View Drop Down

Forum Software by Web Wiz Forums® version 12.01
Copyright ©2001-2018 Web Wiz Ltd.